Night Blindness: The Failing Rod System and Impaired Dark Adaptation

Abstract

Night blindness, or nyctalopia, is impaired vision in dim light: not a disease but a symptom, the perceptual signature of a failing rod system, the branch of the retina that mediates vision under low illumination. Because the rods are sensitive photoreceptors that recover their pigment slowly, anything that starves, mis-wires, or destroys them leaves a person helpless once the cones fall silent. The symptom therefore points with unusual precision to one physiological system, useful clinically and instructive in the laboratory. This article covers the rod machinery and the dark-adaptation curve whose failure produces it, its three causal groups — reversible vitamin A deficiency, stationary inherited defects, and progressive degenerations — and how they are distinguished. Three interactive demonstrations trace the two-limbed curve, the retinoid cycle’s rate, and the thousandfold sensitivity the rod limb buys.

Keywords: night blindness, nyctalopia, dark adaptation, rod photoreceptors

Night blindness is among the oldest recorded medical complaints: the ancient Egyptians treated it with roasted ox liver, an unwitting but effective delivery of vitamin A, millennia before the vitamin or the rods were known. What unites its many modern causes is a single functional endpoint — the loss of scotopic vision, the dim-light seeing carried by the rod photoreceptors — while photopic, cone-mediated daylight vision is left intact. A person with night blindness reads an eye chart normally and moves confidently through a lit room, then becomes helpless the moment the light drops below the level at which cones can operate (Zeitz et al., 2015).

This selectivity is the whole story. The rod and cone systems are anatomically intermixed but functionally separate, with distinct pigments, distinct sensitivities, and distinct operating ranges. Night blindness is what it looks like from the outside when the rod system is subtracted, and its differential diagnosis is essentially a catalogue of the ways that system can break: the pigment can run short of its vitamin-A raw material, the rod's signal can fail to reach the neurons downstream, or the rods themselves can degenerate. The sections below move from what the symptom is, through the rod machinery and the dark-adaptation process whose failure produces it, to the principal causes and how they are told apart at the bedside.

Key Takeaways

Night blindness (nyctalopia) is a symptom — impaired vision in dim light — not a disease; it signals a failure of the rod system while cone-mediated daylight vision is preserved (Zeitz et al., 2015).
The rods are the dim-light photoreceptors, so sensitive that a fully dark-adapted rod can register a single quantum of light (Hecht et al., 1942).
Rod vision depends on rhodopsin, regenerated through the vitamin-A–based retinoid cycle; a break anywhere in that supply chain impairs dark adaptation (Lamb & Pugh, 2004).
The great causes divide into the reversible (vitamin A deficiency), the stationary and inherited (congenital stationary night blindness), and the progressive (retinitis pigmentosa and related degenerations) (Sommer, 2008; Hartong et al., 2006).
The symptom is diagnostically precise because it isolates one physiological system, but the prognosis it carries ranges from complete cure to inexorable blindness depending on the cause (Duncan et al., 2018).

Figure 1

The Dark-Adaptation Curve and the Rod-Cone Break

Note. In the dark-adapted eye the visual threshold recovers in two limbs. The fast cone limb (gold) levels off within a few minutes; at the rod-cone break the more sensitive rod limb (navy) takes over and drives the threshold down by a further ~3 log units over some 20–30 minutes. In night blindness (dashed red) the rod limb is absent or grossly elevated, so the person is stranded at the cone plateau — roughly a thousand times less sensitive in the dark than a normal observer. Schematic, after Lamb and Pugh (2004).

What Night Blindness Is

Night blindness is difficulty seeing in dim light or darkness. The term nyctalopia names the symptom, not any single cause, and this is the first thing to be clear about: it is a functional complaint, reported by the patient or elicited by testing, that many different underlying conditions can produce. In Medical Subject Headings the descriptor sits among the vision disorders, and it is deliberately broad, because the same experience — the world going dark faster and more completely than it should as the light fades — can arise from a vitamin deficiency, an inherited defect present from birth, or a degenerative disease of the retina (Zeitz et al., 2015).

What makes the complaint diagnostically valuable is its specificity to a system. Human vision is duplex: the cones handle bright light, fine detail, and colour, while the rods handle dim light, and the two operate over largely non-overlapping ranges of illumination. Night blindness is the perceptual consequence of losing the rod branch while keeping the cone branch. The patient sees perfectly well by day and in a lit room, and their visual acuity measured on a chart may be entirely normal, because acuity is a cone-mediated, high-luminance measurement. The deficit appears only where the rods are supposed to take over — at dusk, in an unlit street, in a dim restaurant, in the transition from sunlight into a cinema (Fain et al., 2001).

The critical distinction that organises everything downstream is between night blindness that is stationary and night blindness that is progressive. Some causes — the congenital stationary forms, and a corrected vitamin deficiency — produce a fixed deficit that does not worsen over time, and may be entirely benign or fully reversible. Others — retinitis pigmentosa and its relatives — are the opening symptom of a relentless degeneration that goes on to take the peripheral visual field and, eventually, sight itself (Hartong et al., 2006). The same complaint can thus be trivial or ominous, and telling which is the central task of assessment.

The Rod System and Dark Adaptation

To understand any form of night blindness one must understand what the rods do and how they recover their sensitivity in the dark. The rods are photoreceptors specialised for dim light, and they dominate the retina by sheer number: the classic anatomical mapping found roughly 92 million rods to only about 4.6 million cones, the rods absent from the very centre but blanketing the periphery (Curcio et al., 1990). Their sensitivity is astonishing: the classic quantum experiment showed that a fully dark-adapted observer can detect a flash delivering only a handful of photons to the retina, so few that each is almost certainly absorbed by a different rod — meaning a single rod responds to a single quantum of light (Hecht et al., 1942). This sensitivity is the whole point of the rod system, and it is exactly what night blindness removes.

That sensitivity is achieved through a visual pigment, rhodopsin, and it is not free: a molecule of rhodopsin that has absorbed a photon is bleached and must be regenerated before it can catch light again. The chemistry of that photon capture — how the absorption of light by the pigment initiates the neural signal — was worked out in the biochemistry of visual excitation, which showed that the light-sensitive component is a derivative of vitamin A bound to a protein (Wald, 1968). Regeneration runs through the retinoid cycle, a biochemical loop that shuttles vitamin-A derivatives between the photoreceptors and the neighbouring retinal pigment epithelium, converting the spent all-trans form back into the 11-cis form the pigment needs (Lamb & Pugh, 2004). The rate of this cycle sets the rate at which sensitivity returns in the dark, and every nutritional and enzymatic cause of night blindness is, at bottom, a disturbance of it.

Dark adaptation is the process by which vision recovers its sensitivity after exposure to light, and its time course is the functional fingerprint of the rod system. Plotted as threshold against time in the dark, it falls in two limbs: a rapid cone limb that reaches its floor within a few minutes, and then, at the rod-cone break, a slower rod limb that continues downward for twenty to thirty minutes until the eye reaches its final, vastly lower threshold — roughly three log units, a factor of about a thousand, below the cone plateau (Fain et al., 2001). This two-limbed curve is Figure 1, and night blindness is what happens to it when the rod limb is missing, delayed, or elevated. Where the fault lies in the rod machinery determines which part of the curve is abnormal, which is why dark adaptometry is so informative a test.

The dark-adaptation curve and the missing rod limb

In the dark, visual threshold falls in two stages. A fast cone limb reaches its floor within a few minutes; then, at the rod-cone break, a slow rod limb carries threshold down another three log units — a thousandfold gain in sensitivity — over twenty to thirty minutes. Night blindness is what happens when that rod limb is missing: the eye adapts as far as the cones allow and no further. Toggle the night-blind curve and move the probe to read off how far apart the two observers are at any moment in the dark.

Time in the dark

At 20 min in the dark, the normal eye's threshold sits 0.22 log units above the fully dark-adapted floor. Show the night-blind curve to compare the two observers.

Schematic two-limbed dark-adaptation curve after Fain et al. (2001). The night-blind curve holds the normal cone limb and removes the rod limb; exact kinetics vary with the bleaching light and the individual.

Causes of Night Blindness

Because night blindness is a symptom, its causes are best organised by the level at which the rod system fails, and the resulting three groups differ radically in prognosis. The first is nutritional: deficiency of vitamin A, the raw material of the visual pigment. Where diet is short of it — still a major public-health problem in parts of the world — the retinoid cycle cannot regenerate enough rhodopsin, and night blindness is the earliest ocular sign, appearing before the more devastating corneal damage of advanced deficiency. It is the reversible cause par excellence: replacing the vitamin restores rod function, which is why the historical liver remedy worked and why vitamin A supplementation remains a cornerstone of global child health (Sommer, 2008).

The second group is the congenital stationary night blindnesses (CSNB), a family of inherited conditions in which the rods capture light normally but the signal fails to propagate correctly to the neurons downstream. These are, as the name insists, stationary: present from birth and non-progressive, so vision does not deteriorate over time. The electroretinogram revealed their mechanism — a characteristic negative waveform in which the light-evoked a-wave is preserved but the b-wave, generated by the bipolar cells receiving the rod signal, is selectively reduced, localising the defect to signal transmission at the first synapse rather than to the photoreceptor itself (Miyake et al., 1986). Genetically the family is heterogeneous; one instructive form is caused not by a transmission defect but by a mutation in rhodopsin itself that leaves the pigment constitutively active, as if perpetually seeing light, so that the rod cannot signal a real photon against its own noise (Dryja et al., 1993). The systematic dissection of CSNB genotypes and their matching electrophysiology is among the field's more complete genotype-phenotype maps (Zeitz et al., 2015).

The third group is the progressive retinal degenerations, and here night blindness is the harbinger of something grave. In retinitis pigmentosa and its relatives the rods do not merely misfire; they die, and their death is the leading edge of a degeneration that goes on to consume the peripheral field and threaten sight (Hartong et al., 2006). Because the rods degenerate first, night blindness is characteristically the presenting complaint, preceding the ring scotoma and tunnel vision by years, and the sheer genetic heterogeneity of the non-syndromic disease — dozens of causative genes converging on the same rod-first phenotype — is what makes molecular diagnosis both difficult and decisive (Verbakel et al., 2018). A revealing intermediate case is fundus albipunctatus, a form of stationary night blindness caused by mutations in the enzyme 11-cis retinol dehydrogenase (RDH5): here the retinoid cycle runs abnormally slowly, so dark adaptation is enormously prolonged — a normal final threshold is eventually reached, but only after hours rather than minutes — showing in one condition how directly the kinetics of the cycle set the kinetics of recovery (Yamamoto et al., 1999). The practical upshot is that the single symptom of failing to see at night spans conditions requiring nothing more than a dietary supplement and conditions marking the start of irreversible blindness, and distinguishing them is urgent. The three groups are summarised in Table 1.

Table 1. The three causal groups of night blindness, distinguished by the level at which the rod system fails, the signature each leaves on functional testing, and its prognosis.
Group	Where the rod system fails	Signature on testing	Course and prognosis
Nutritional (vitamin A deficiency)	Too little vitamin A to regenerate rhodopsin, starving the retinoid cycle of its raw material.	Elevated rod threshold on dark adaptometry that normalises with repletion; the earliest ocular sign, before corneal damage.	Reversible — fully corrected by vitamin A. A treatable sentinel of a lethal deficiency.
Congenital stationary (CSNB)	Rods capture light but the signal fails to cross the first synapse — or a mutated pigment is constitutively active.	Negative ERG: preserved a-wave, selectively reduced b-wave; rod limb absent or elevated from birth.	Stationary — present from birth, non-progressive; vision does not deteriorate.
Progressive degenerations (e.g. retinitis pigmentosa)	The rods themselves die, the leading edge of a spreading photoreceptor degeneration.	Reduced-a-wave (photoreceptor) ERG; rod limb progressively lost as the peripheral field narrows.	Progressive — heralds sight-threatening degeneration; molecular diagnosis now guides gene therapy.

The retinoid cycle: how fast the pigment comes back

Every rhodopsin molecule that catches a photon is bleached and must be regenerated before it can catch another. Regeneration runs through the retinoid cycle, which recycles vitamin-A derivatives between the rods and the neighbouring pigment epithelium. The rate of that cycle sets the rate at which rod sensitivity returns in the dark. Slow the cycle — too little vitamin A, or a sluggish enzyme like RDH5 — and dark adaptation is prolonged, the mechanistic root of several forms of night blindness. Drag the cycle rate and watch regeneration slow.

Retinoid-cycle rate (% of normal)

At 100% of the normal cycle rate, only 92% of pigment is back after 15 minutes in the dark, and reaching 90% regeneration takes about 14 minutes — 1.0× the normal time. This is normal retinoid cycle. recovery near-normal

First-order regeneration kinetics (normal τ = 6 min) after Lamb & Pugh (2004), illustrative. In fundus albipunctatus a slow RDH5 enzyme stretches recovery from minutes to hours while the final threshold stays normal.

Diagnosis and Assessment

The assessment of night blindness follows directly from its physiology: the aim is to confirm that the rod system is at fault and then to localise the fault well enough to separate the reversible, the stationary, and the progressive. The history does much of this work. Lifelong, non-worsening difficulty in the dark, especially with a family history, points to a congenital stationary form; recent onset with a dietary or malabsorptive risk factor points to vitamin A deficiency; and difficulty that is worsening, particularly if accompanied by a narrowing field, raises the spectre of a progressive degeneration (Zeitz et al., 2015).

Two functional tests anchor the objective assessment. Dark adaptometry measures the recovery of threshold in the dark directly, tracing the two-limbed curve of Figure 1: it reveals whether the rod limb is absent (as in severe CSNB), merely delayed (as in the slowed retinoid cycle of fundus albipunctatus), or elevated in a way that worsens on serial testing (as in a degeneration). Because it reads out the very process that night blindness disturbs, it is the most direct physiological confirmation of the symptom, and the RDH5 case shows its discriminating power — only a test that waits long enough sees the eventual normal threshold that separates that benign condition from a progressive one (Yamamoto et al., 1999).

The electroretinogram (ERG) complements it by dissecting where in the rod pathway the fault lies. The scotopic ERG separates the a-wave, the photoreceptors' own response, from the b-wave, generated by the downstream bipolar cells; the negative ERG of the Schubert-Bornschein type of CSNB — preserved a-wave, selectively reduced b-wave — pins the defect to signal transmission at the first synapse and distinguishes it at a stroke from the reduced-a-wave pattern of a photoreceptor degeneration (Miyake et al., 1986). Increasingly these functional tests are joined by genetic testing, which both confirms the specific diagnosis within the heterogeneous CSNB family and, for the degenerations, carries the prognostic and now therapeutic weight that molecular diagnosis has acquired across inherited retinal disease (Duncan et al., 2018).

Worked Example

The functional cost of night blindness can be made quantitative by looking at the dark-adaptation curve it removes. Over the rod limb, the log threshold falls from the cone plateau to the final dark-adapted level by about Δ = 3.0 log units — a sensitivity gain of 10^3.0 = 1,000-fold. That is the size of the deficit a night-blind person who lacks a working rod limb is left with: in the fully dark-adapted state they need on the order of a thousand times more light to see than a normal observer does.

The recovery of the normal rod limb can be modelled, illustratively, as an approach to that final threshold with a time constant τ. Writing the fraction of the log gap still to be closed as

remaining(t) = e^−t/τ, with τ = 5 minutes

the time to close half the gap — to recover 1.5 of the 3.0 log units — is

t = τ · ln(2) = 5 × 0.693 ≈ 3.5 minutes

and the time to come within a tenth of the final threshold (to close 90% of the gap) is

t = τ · ln(10) = 5 × 2.303 ≈ 11.5 minutes

Projecting the sensitivity gain forward along the rod limb makes the cost of losing it concrete:

after 10 minutes: gap closed 1 − e⁻² = 86.5%, a drop of 2.59 log units → about 390× more sensitive

after 20 minutes: gap closed 1 − e⁻⁴ = 98.2%, a drop of 2.95 log units → about 880×

after 30 minutes: gap closed 1 − e⁻⁶ = 99.8%, a drop of 2.99 log units → about 980×

The lesson is in the gap the rod limb closes and the person with night blindness cannot. A normal observer, over half an hour in the dark, becomes nearly a thousand times more sensitive than they were at the cone plateau; someone whose rod limb is absent stays stranded near that plateau. This is why the deficit is invisible by day and total by night: the scotopic range that the rods add spans roughly three log units below the cone floor — the difference between seeing by starlight and seeing nothing at all. The time constant here is illustrative, and real dark-adaptation kinetics vary with the bleaching light and the individual; the robust facts are the ~3-log-unit final gain and its slow, minutes-long recovery. The demonstration below lets the rod-limb parameters be varied to see how the curve, the rod-cone break, and the final deficit respond.

The sensitivity the rod limb buys — and night blindness forfeits

Over the rod limb, log threshold falls by about Δ log units with a time constant τ, so the normal eye gains 10^Δ-fold in sensitivity while the night-blind eye, lacking the limb, gains none. Set the size of the rod range and how fast it recovers, then move the probe to read the sensitivity already gained and the total the night-blind observer never gets. The defaults reproduce the worked example: Δ = 3.0 log units, τ = 5 min.

Rod range Δ (log units)

Recovery time constant τ (min)

Time in the dark

With Δ = 3.0 log units and τ = 5 min, half the gap closes in 3.5 min and 90% in 11.5 min. After 20 min the normal eye has gained 2.95 log units — about 881×. The full rod limb is worth 1,000×, every bit of which the night-blind observer forfeits.

Illustrative exponential recovery of the rod limb; the defaults (Δ = 3.0, τ = 5 min) reproduce the arithmetic of the Worked Example. Real kinetics depend on the bleaching light and the observer.

Discussion

Night blindness occupies an unusual position in the vision sciences: it is a symptom precise enough to name a physiological system. Most clinical complaints are ambiguous about their origin, but the report of failing vision in the dark, properly interrogated, points almost unerringly at the rod branch of the duplex retina. This is why night blindness has served, historically, as a natural probe of scotopic vision — the condition confirms from the clinic what the psychophysics of dark adaptation and the quantum theory of vision established in the laboratory, that human vision is two systems and not one, with the rod system carrying a sensitivity range some three log units beyond the reach of the cones (Hecht et al., 1942; Fain et al., 2001).

The symptom's real subtlety is that a single perceptual endpoint is reached by mechanistically distinct routes, and the discipline of the field has been to keep those routes apart. A shortage of the pigment's vitamin-A raw material, a failure of the rod's signal to cross its first synapse, an abnormally slow retinoid cycle, and the outright death of the rods all present as difficulty seeing at night, yet they differ in everything that matters — in mechanism, in the shape of the dark-adaptation curve and the ERG, and above all in prognosis (Zeitz et al., 2015). The clinical and scientific achievement has been to build tests that read the mechanism off the symptom: dark adaptometry that separates absent from merely delayed recovery, and the ERG that separates a transmission defect from a photoreceptor one.

That mechanistic separation is not academic, because it determines whether the same complaint calls for a vitamin capsule or foreshadows blindness. Vitamin A deficiency, the commonest cause worldwide, is fully reversible and preventable, and the recognition that night blindness is its earliest sign turned the symptom into a sentinel for a treatable and lethal deficiency in child health (Sommer, 2008). At the other pole, the night blindness that opens retinitis pigmentosa is the first sign of a degeneration that, until very recently, medicine could only watch (Hartong et al., 2006). The value of the symptom lies precisely in this range: it is the same door opening onto opposite outcomes, and the whole of its clinical importance is in knowing which.

Current Directions

The most consequential recent progress touches the incurable end of the spectrum. For the progressive degenerations that night blindness so often announces, gene-replacement therapy has moved from aspiration to approved treatment: a therapy targeting the RPE65 gene of the retinoid cycle — the same cycle whose disturbance underlies so many forms of impaired dark adaptation — became the first gene therapy approved for an inherited retinal disease, correcting the molecular defect at its source in the small subset of patients who carry that mutation (Russell et al., 2017). Because it repairs one specific gene, its very existence has made molecular diagnosis essential, turning the question behind every case of degenerative night blindness from one of prognosis into one of molecular identity: which gene, and is it treatable.

For the stationary forms, the frontier is genetic and mechanistic rather than therapeutic. The congenital stationary night blindnesses have become a model system for the rod-to-bipolar synapse, with the growing catalogue of CSNB genes mapping, one by one, the molecular components of signal transmission at the first synapse of vision — each new gene a lesion that dissects the pathway (Zeitz et al., 2015). More broadly, the field has begun to take stock of how much of the inherited-retinal-disease landscape remains without a molecular diagnosis or a treatment, framing the unmet need and the knowledge gaps that the next decade of gene discovery and therapy must close (Duncan et al., 2018). The scale of that need is now being quantified: recent burden-of-disease work on retinitis pigmentosa — the progressive degeneration that night blindness most often heralds — documents a substantial and largely unmet demand for effective therapy, the human cost behind the molecular science (Cross et al., 2022). The trajectory across the whole differential of night blindness — from a nutritional deficiency long since understood, through a stationary family being mapped gene by gene, to progressive degenerations now yielding to molecular repair — is among the more hopeful in clinical neuroscience.

Common Misconceptions

“Night blindness means total blindness in the dark.”: Not usually. It means dim-light vision is impaired or slow to develop, not that it is wholly absent. Many people with night blindness see poorly and slowly in the dark rather than not at all, and the severity depends entirely on the cause — from a subtle delay in dark adaptation to a near-total loss of the rod contribution (Zeitz et al., 2015).
“Night blindness is a disease.”: It is a symptom, not a diagnosis. The same complaint can arise from a vitamin deficiency, an inherited stationary defect, or a progressive degeneration, and these differ in mechanism and prognosis. Naming the symptom is only the beginning of finding its cause (Duncan et al., 2018).
“Eating carrots will improve anyone's night vision.”: Only when the cause is vitamin A deficiency. Vitamin A restores rod function in the deficient, which is a real and important cure worldwide, but it does nothing for night blindness caused by an inherited transmission defect or a retinal degeneration, where the raw material is not what is lacking (Sommer, 2008).
“All night blindness gets worse over time.”: Many forms are stationary by definition. The congenital stationary night blindnesses are present from birth and do not progress, and corrected vitamin A deficiency is reversible. It is specifically the progressive degenerations, such as retinitis pigmentosa, that worsen — which is why distinguishing them matters so much (Hartong et al., 2006).

Glossary

Cone.: The photoreceptor specialised for bright light, fine detail, and colour; its daylight function is preserved in night blindness, which is why acuity by day is normal.
Congenital stationary night blindness (CSNB).: A family of inherited, non-progressive conditions in which the rods capture light but the signal fails to transmit normally to the downstream neurons, producing lifelong but stable night blindness.
Dark adaptation.: The recovery of visual sensitivity in darkness as the photoreceptors regenerate their pigment; its rod branch is the process whose failure produces night blindness.
Dark adaptometry.: The clinical measurement of the dark-adaptation curve over time, used to reveal whether the rod contribution is absent, delayed, or elevated, and so to characterise the failing rod system objectively.
Electroretinogram (ERG).: A recording of the retina's massed electrical response to light; its scotopic form localises a rod-pathway fault, and the negative ERG marks a transmission defect at the first synapse.
Fundus albipunctatus.: A stationary night blindness caused by RDH5 mutations that slow the retinoid cycle, greatly prolonging dark adaptation so that a normal threshold is reached only after hours.
Negative ERG.: An electroretinogram in which the photoreceptor a-wave is preserved but the bipolar-cell b-wave is selectively reduced, indicating a defect in signal transmission rather than in the photoreceptors.
Nyctalopia.: The medical term for night blindness: impaired vision in dim light or darkness, a symptom of rod-system failure rather than a disease in itself.
Retinoid cycle.: The biochemical loop that recycles vitamin-A derivatives between the photoreceptors and the pigment epithelium to regenerate visual pigment; its rate sets the rate of dark adaptation.
Rhodopsin.: The visual pigment of the rods, a vitamin-A derivative bound to a protein; it is bleached by light and must be regenerated through the retinoid cycle before it can catch light again.
Rod-cone break.: The point on the dark-adaptation curve, some 7–10 minutes into the dark, at which the more sensitive rod system overtakes the cones and the threshold resumes falling.
Rod.: The photoreceptor specialised for dim light, so sensitive it can respond to a single quantum; the cell whose dysfunction or loss underlies every form of night blindness.
Scotopic vision.: Vision under low-light conditions, mediated by the rod system; the branch of vision selectively lost in night blindness.
Vitamin A deficiency.: A nutritional shortage of the vitamin from which visual pigment is built; the commonest and most reversible cause of night blindness worldwide, and its earliest ocular sign.

Key Researchers

Isabelle Audo

(living). Professor-practitioner ophthalmologist at the Institut de la Vision and the Quinze-Vingts National Ophthalmology Hospital, Paris, who co-leads the inherited-retinal-disease team and co-authored the definitive analysis of congenital stationary night blindness (Zeitz et al., 2015). ORCID · Faculty page

Selig Hecht

(1892–1947). Biophysicist at Columbia University whose quantum experiment on the absolute threshold of vision showed that a dark-adapted rod can register a single photon, establishing the quantitative bedrock of scotopic sensitivity that night blindness abolishes (Hecht et al., 1942). Wikipedia

Trevor D. Lamb

(living). Emeritus Professor at the Australian National University and Fellow of the Royal Society, whose work on phototransduction and the retinoid cycle framed the molecular basis of dark adaptation and its failure, the process at the heart of night blindness (Lamb & Pugh, 2004). Faculty page · Wikidata

Cynthia Owsley

(living). Professor of Ophthalmology and Visual Sciences at the University of Alabama at Birmingham, whose work on rod-mediated dark adaptation and its slowing in aging and disease made delayed dark adaptation a measurable functional endpoint (Jackson et al., 1999). ORCID · Faculty page

Alfred Sommer

(b. 1942, living). Ophthalmologist and epidemiologist, Dean Emeritus of the Johns Hopkins Bloomberg School of Public Health, whose field trials established vitamin A deficiency — of which night blindness is the earliest ocular sign — as a driver of childhood mortality, making its treatment a pillar of global child health (Sommer, 2008). Faculty page

George Wald

(1906–1997). Harvard biochemist and Nobel laureate whose work on the chemistry of vision identified the vitamin-A–derived chromophore of rhodopsin, tying dietary vitamin A directly to rod function and explaining at the molecular level why its deficiency causes night blindness (Wald, 1968). Nobel biography · Wikipedia

Christina Zeitz

(living). Research director at the Institut de la Vision, Sorbonne Universite, Paris, and a leading authority on the genetics of congenital stationary night blindness, senior author of the definitive review mapping its genotype-phenotype correlations and pathogenic mechanisms (Zeitz et al., 2015). ORCID · Faculty page

Frequently Asked Questions

What is night blindness?

Night blindness, or nyctalopia, is difficulty seeing in dim light or darkness. It is a symptom rather than a disease, and it signals that the rod photoreceptors — the cells that carry vision in low light — are not working properly, while the cones that serve daylight vision remain intact.

Why can someone with night blindness see perfectly well by day?

Because daylight vision is carried by the cones, and night blindness affects only the rods. The two photoreceptor systems operate over almost separate ranges of light, so a person can have entirely normal visual acuity on an eye chart, and move confidently through a lit room, yet be unable to see once the light drops to the level where rods must take over.

What causes night blindness?

The causes divide into three groups. Vitamin A deficiency starves the rods of the raw material for their visual pigment and is the commonest and most reversible cause worldwide. Congenital stationary night blindness is a group of inherited, non-progressive defects in rod signalling present from birth. And progressive retinal degenerations, such as retinitis pigmentosa, destroy the rods over time.

Is night blindness curable?

It depends entirely on the cause. When it is due to vitamin A deficiency it is fully reversible with the vitamin. The congenital stationary forms do not worsen but cannot at present be reversed, though they are often compatible with a normal life. Night blindness from a progressive degeneration is the one that carries a serious prognosis, and treatments for those are only beginning to emerge.

Will eating carrots or taking vitamin A help?

Only if the cause is vitamin A deficiency, in which case it is genuinely curative. Vitamin A does nothing for night blindness caused by an inherited transmission defect or a retinal degeneration, because in those conditions the raw material for the pigment is not what is missing.

How is night blindness diagnosed?

Through the patient's history, dark adaptometry, and the electroretinogram. Dark adaptometry measures how the eye recovers its sensitivity in the dark and shows whether the rod contribution is absent, delayed, or elevated. The electroretinogram localises the fault within the rod pathway, distinguishing a signalling defect from the death of the photoreceptors themselves.

Is night blindness the same as being unable to see in complete darkness?

No. Everyone is effectively blind in total darkness, because vision needs at least some light. Night blindness is impaired vision in dim light — the reduced or absent ability of the rod system to make use of the little light that is present, such as starlight or a dim streetlight, that a normal eye would exploit.

When should night blindness be taken seriously?

Any new or worsening difficulty seeing in the dark deserves assessment, but it is especially important when the difficulty is progressing, when it is accompanied by a narrowing of side vision, or when there is a family history of retinal disease, because those features point toward a progressive degeneration rather than a benign or reversible cause.

References

Cross, N., van Steen, C., Zegaoui, Y., Satherley, A., & Angelillo, L. (2022). Retinitis pigmentosa: Burden of disease and current unmet needs. Clinical Ophthalmology, 16, 1993–2010. https://doi.org/10.2147/OPTH.S365486

Curcio, C. A., Sloan, K. R., Kalina, R. E., & Hendrickson, A. E. (1990). Human photoreceptor topography. The Journal of Comparative Neurology, 292(4), 497–523. https://doi.org/10.1002/cne.902920402

Dryja, T. P., Berson, E. L., Rao, V. R., & Oprian, D. D. (1993). Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nature Genetics, 4(3), 280–283. https://doi.org/10.1038/ng0793-280

Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., & Zarbin, M. A. (2018). Inherited retinal degenerations: Current landscape and knowledge gaps. Translational Vision Science & Technology, 7(4), 6. https://doi.org/10.1167/tvst.7.4.6

Fain, G. L., Matthews, H. R., Cornwall, M. C., & Koutalos, Y. (2001). Adaptation in vertebrate photoreceptors. Physiological Reviews, 81(1), 117–151. https://doi.org/10.1152/physrev.2001.81.1.117

Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006). Retinitis pigmentosa. The Lancet, 368(9549), 1795–1809. https://doi.org/10.1016/S0140-6736(06)69740-7

Hecht, S., Shlaer, S., & Pirenne, M. H. (1942). Energy, quanta, and vision. The Journal of General Physiology, 25(6), 819–840. https://doi.org/10.1085/jgp.25.6.819

Jackson, G. R., Owsley, C., & McGwin, G. (1999). Aging and dark adaptation. Vision Research, 39(23), 3975–3982. https://doi.org/10.1016/S0042-6989(99)00092-9

Lamb, T. D., & Pugh, E. N. (2004). Dark adaptation and the retinoid cycle of vision. Progress in Retinal and Eye Research, 23(3), 307–380. https://doi.org/10.1016/j.preteyeres.2004.03.001

Miyake, Y., Yagasaki, K., Horiguchi, M., Kawase, Y., & Kanda, T. (1986). Congenital stationary night blindness with negative electroretinogram: A new classification. Archives of Ophthalmology, 104(7), 1013–1020. https://doi.org/10.1001/archopht.1986.01050190071042

Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., Cross, D., Marshall, K. A., Walshire, J., Kehoe, T. L., Reichert, H., Davis, M., Raffini, L., George, L. A., Hudson, F. P., … Maguire, A. M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. The Lancet, 390(10097), 849–860. https://doi.org/10.1016/S0140-6736(17)31868-8

Sommer, A. (2008). Vitamin A deficiency and clinical disease: An historical overview. The Journal of Nutrition, 138(10), 1835–1839. https://doi.org/10.1093/jn/138.10.1835

Verbakel, S. K., van Huet, R. A. C., Boon, C. J. F., den Hollander, A. I., Collin, R. W. J., Klaver, C. C. W., Hoyng, C. B., Roepman, R., & Klevering, B. J. (2018). Non-syndromic retinitis pigmentosa. Progress in Retinal and Eye Research, 66, 157–186. https://doi.org/10.1016/j.preteyeres.2018.03.005

Wald, G. (1968). The molecular basis of visual excitation. Nature, 219(5156), 800–807. https://doi.org/10.1038/219800a0

Yamamoto, H., Simon, A., Eriksson, U., Harris, E., Berson, E. L., & Dryja, T. P. (1999). Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. Nature Genetics, 22(2), 188–191. https://doi.org/10.1038/9707

Zeitz, C., Robson, A. G., & Audo, I. (2015). Congenital stationary night blindness: An analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Progress in Retinal and Eye Research, 45, 58–110. https://doi.org/10.1016/j.preteyeres.2014.09.001

Night Blindness